JP2017002092A5 - - Google Patents

Download PDF

Info

Publication number
JP2017002092A5
JP2017002092A5 JP2016202730A JP2016202730A JP2017002092A5 JP 2017002092 A5 JP2017002092 A5 JP 2017002092A5 JP 2016202730 A JP2016202730 A JP 2016202730A JP 2016202730 A JP2016202730 A JP 2016202730A JP 2017002092 A5 JP2017002092 A5 JP 2017002092A5
Authority
JP
Japan
Prior art keywords
starch
pharmaceutically acceptable
acceptable salt
calcium
canagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016202730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017002092A (ja
JP6639368B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017002092A publication Critical patent/JP2017002092A/ja
Publication of JP2017002092A5 publication Critical patent/JP2017002092A5/ja
Application granted granted Critical
Publication of JP6639368B2 publication Critical patent/JP6639368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016202730A 2014-12-25 2016-10-14 糖尿病治療用固形製剤 Active JP6639368B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014262702 2014-12-25
JP2014262702 2014-12-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016546861A Division JP6027710B1 (ja) 2014-12-25 2015-12-24 糖尿病治療用固形製剤

Publications (3)

Publication Number Publication Date
JP2017002092A JP2017002092A (ja) 2017-01-05
JP2017002092A5 true JP2017002092A5 (cg-RX-API-DMAC7.html) 2019-01-31
JP6639368B2 JP6639368B2 (ja) 2020-02-05

Family

ID=56150656

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546861A Active JP6027710B1 (ja) 2014-12-25 2015-12-24 糖尿病治療用固形製剤
JP2016202730A Active JP6639368B2 (ja) 2014-12-25 2016-10-14 糖尿病治療用固形製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016546861A Active JP6027710B1 (ja) 2014-12-25 2015-12-24 糖尿病治療用固形製剤

Country Status (2)

Country Link
JP (2) JP6027710B1 (cg-RX-API-DMAC7.html)
WO (1) WO2016104643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508385A (ja) * 2017-02-03 2019-03-28 グレンマーク・ファーマシューティカルズ・リミテッド テネリグリプチンのシュウ酸塩およびその溶媒和物、中間体、その調製方法およびマーカー
WO2020209350A1 (ja) * 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるsglt-2阻害剤の使用
JPWO2024053680A1 (cg-RX-API-DMAC7.html) * 2022-09-07 2024-03-14

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602008003522D1 (de) * 2007-02-01 2010-12-30 Takeda Pharmaceutical Feste zubereitung mit alogliptin und pioglitazon
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2514422B1 (en) * 2009-12-18 2016-08-10 Mitsubishi Tanabe Pharma Corporation Elution stabilized teneligliptin preparation
EP2568971B1 (en) * 2010-05-11 2020-10-14 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets

Similar Documents

Publication Publication Date Title
ES2455195T3 (es) Comprimido que se disgrega en la cavidad oral
JP5399749B2 (ja) プロトンポンプ阻害剤を含有する被覆微粒子
JP2021001192A5 (cg-RX-API-DMAC7.html)
TWI526210B (zh) Oral pharmaceutical composition
US20120093738A1 (en) Taste-masked oral formulations of influenza antivirals
JP2017002092A5 (cg-RX-API-DMAC7.html)
US20100183730A1 (en) High dose composition of ursodeoxycholic acid
JP5174909B2 (ja) 活性成分のコーティング膜が保護される口腔内崩壊剤形を製造するための組成物
JPWO2004078171A1 (ja) 吸水性アミノ酸含有錠剤
JP6164346B2 (ja) 口腔内崩壊錠の製造方法
JP5572321B2 (ja) 被覆微粒子含有口腔内崩壊錠
JP2013237651A (ja) ピタバスタチンの口腔内崩壊錠
JP2016027007A (ja) ビタミンb12含有組成物
JP2005139085A (ja) 顆粒
JP2018145095A (ja) エルロチニブ塩酸塩含有医薬組成物
JP2005298373A (ja) 吸水性アミノ酸含有糖衣錠剤
TW201716063A (zh) 維生素c和鋅之穩定組合物錠劑
JP5828280B2 (ja) 錠剤及びその製造方法
JP7023600B2 (ja) シロドシン含有医薬組成物とその製造方法
JP7023186B2 (ja) 認知症治療薬を含有する口腔内崩壊性錠剤
JP6601844B2 (ja) 光安定性に優れたミルタザピン含有医薬製剤
JP6198329B2 (ja) 積層錠及びその製造方法
JP7480983B2 (ja) レベチラセタム含有製剤
RU2286143C1 (ru) Муколитическая фармацевтическая композиция
JP6853828B2 (ja) メマンチンまたはその薬学上許容される塩を含有する医薬組成物